Brokers Set Expectations for Aethlon Medical Q2 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Analysts at HC Wainwright issued their Q2 2027 earnings per share estimates for Aethlon Medical in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth forecasts that the medical equipment provider will post earnings per share of ($3.64) for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.50 price target on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($16.15) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

AEMD has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Aethlon Medical has an average rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Stock Performance

AEMD stock opened at $2.78 on Thursday. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00. The stock has a market capitalization of $1.97 million, a PE ratio of -0.08 and a beta of 1.41. The company has a fifty day moving average of $4.40 and a 200-day moving average of $8.51.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.92) by ($0.10).

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent filing with the SEC. 1.99% of the stock is owned by institutional investors and hedge funds.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.